CADTH Canadian Drug Expert Committee, & Canadian Agency for Drugs and Technologies in Health. (2018). CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.): Indication : adult patients with active psoriatic arthritis (PsA) who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD) (Version 1.0.). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health.
Chicago Style CitationCADTH Canadian Drug Expert Committee, and Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.): Indication : Adult Patients With Active Psoriatic Arthritis (PsA) Who Have Responded Inadequately To, or Are Intolerant to One or More Disease-modifying Antirheumatic Drugs (DMARD). Version 1.0. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2018.
MLA CitationCADTH Canadian Drug Expert Committee, and Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.): Indication : Adult Patients With Active Psoriatic Arthritis (PsA) Who Have Responded Inadequately To, or Are Intolerant to One or More Disease-modifying Antirheumatic Drugs (DMARD). Version 1.0. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2018.